InvestorsHub Logo
Followers 5
Posts 949
Boards Moderated 2
Alias Born 05/28/2019

Re: None

Sunday, 05/21/2023 12:58:44 PM

Sunday, May 21, 2023 12:58:44 PM

Post# of 35404
For a company that bought this ticker about a year and a half ago, I'd say they haven't done sh*t to make a go of it... Investor Relations, what a joke...

Nouveau Life Pharmaceuticals, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

For the Period Ended

March 31, 2023 December 31, 2022

Ordinary Income/Expense

Expense

Advertising and Promotion

107

964.00

Automobile & Travel Expenses

160

1,436.90

Business Licenses and Permits: NV SOS

217

652.00

Bus. Licenses & Permits-Other

7,140

35,700.00

Community Outreach

388

1,165.00

Computer and Internet Expenses

188

562.97

Insurance Expense

128

385.00

Office Supplies

453

1,358.00

Professional Fees

39

352.00

Accounting

232

2,085.00

Business Development

255

2.295.00

Investor Relations

161

1,450.00

Legal

1,250

11,250.00

OTC Markets

3,660

7,429:00

Stock Transfer Agents

667

6,000.00

Rent & Lease Expense

486

4,373.29

Telephone Expense

459.70

Training and Staff Development

205

1,845.00 79,762.86

Total Expense

15,787

Net Ordinary Income

(15.787)
March 31, 2023
(79,762.86)

BASIC AND DILUTED LOSS PER SHARE:

($0.000002)

($0.00001)

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic

6,660,963,733

6,660,963,733

The accompanying notes are an integral part of these financial statements.